blood sample
OtherSample taken to test plasma permeability markers
NCT Number: NCT06292598
Narcolepsy type 1 (NT1) is a rare disease characterized by severe drowsiness, cataplexy, hypnagogic hallucinations, sleep paralysis, poor night sleep, and often obesity. NT1 is caused by irreversible loss of orexin (ORX)/hypocretin neurons in the lateral hypothalamus with decreased ORX levels in the cerebrospinal fluid (CSF). Although the underlying process leading to this destruction remains unclear; an autoimmune origin is suspected.
The study authors recently compared the bacterial communities of the fecal microbiota of NT1 patients and control subjects. Initial results demonstrated a difference in overall bacterial community structure in NT1 compared to controls, as assessed by beta diversity, even after adjusting for body mass index (BMI). The Shannon biodiversity index was also correlated with the duration of NT1 disease. However, no association was found between the structure of the microbial community and the clinical characteristics of NT1 patients.
In 2022, a second study from the SOMNOBANK cohort on a larger population confirmed these results, showing dysbiosis between NT1 patients and the control population. The altered intestinal microbial diversity supports the important role of the environment in the development and pathogenesis of NT1. Other studies have established a link between dysbiosis, intestinal permeability and inflammation in other neuroimmune pathologies. Currently, no study has focused on these phenomena of bacterial translocation, intestinal permeability and immune activation linked to the microbiota in type 1 narcolepsy patients.
The study hypothesis is that NT1 patients with dysbiosis in their intestinal microbiota also present a bacterial translocation with an intestinal origin, leading to a systemic inflammatory syndrome favoring an autoimmune damage destroying hypocretin neurons in the hypothalamus. The study authors suspect that microbial elements (DNA) involved in the autoimmune process could be detected in the CSF. This bacterial translocation could vary over time depending on: i) the progression of the disease and its management; ii) changing dysbiosis and: iii) the increase in intestinal permeability and inflammation.
Interested in participating?
Request Info10 year and older
All sexes
Observational
Nîmes University Hospital, Nîmes, Gard, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for control subjects:
Exclusion criteria
Sample taken to test plasma permeability markers
Sample taken to test microbial diversity and composition
Sample taken to test orexin level
Time frame: Day 0
Circulating plasma r16s DNA (copies/μL)
Time frame: Month 12
Circulating plasma r16s DNA (copies/μL)
Time frame: Day 0
Metagenomic sequencing of all genomes present, compared with international databases, presented as number of reads per species (bacterial, fungal and viral)
Time frame: Day 0
Metabarcoding of 16srDNA of bacterial DNA present in plasma in NT1 patients with 16S rDNA >25 copies/μL, presented as relative abundance of bacterial phyla and genera (%)
Time frame: Month 12
Metabarcoding of 16srDNA of bacterial DNA present in plasma in NT1 patients with 16S rDNA >25 copies/μL, presented as relative abundance of bacterial phyla and genera (%)
Time frame: Day 0
measured by metabarcoding
Time frame: Month 12
measured by metabarcoding
Time frame: Day 0
measured by metabarcoding
Time frame: Month 12
measured by metabarcoding
Time frame: Day 0
Relative abundance of bacterial phyla and genera (%) measured by metabarcoding
Time frame: Month 12
Relative abundance of bacterial phyla and genera (%) measured by metabarcoding
Time frame: Day 0
Measured by ELISA (pg/mL)
Time frame: Month 12
Measured by ELISA (pg/mL)
Time frame: Day 0
Measured by ELISA (μg/mL
Time frame: Month 12
Measured by ELISA (μg/mL
Time frame: Day 0
Measured by ELISA (μg/mL
Time frame: Month 12
Measured by ELISA (μg/mL
Time frame: Day 0
Years
Time frame: Day 0
Years
Time frame: Day 0
Epworth scale
Time frame: Day 0
Narcolepsy Severity Scale
Time frame: Day 0
List
Time frame: Day 0
Minutes
Time frame: Day 0
Number
Time frame: Day 0
Measured by Radio-immuno-assay (pg/ml)
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire de Nīmes
Other
Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients
Acronym: NARCOBIOTE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07646678
Disorders of Excessive Somnolence, Dyssomnias
Shinjuku-ku, Tokyo, Japan
View Trial DetailsNCT06383806
Disorders of Excessive Somnolence, Dyssomnias
Salt Lake City, Utah, United States
View Trial DetailsNCT07598708
Cataplexy, Disorders of Excessive Somnolence
Miami, Florida, United States
View Trial DetailsNCT07540897
Disorders of Excessive Somnolence, Dyssomnias
Miami, Florida, United States
View Trial Details